286 related articles for article (PubMed ID: 27039323)
1. Comparison of 11C-4DST and 18F-FDG PET/CT imaging for advanced renal cell carcinoma: preliminary study.
Minamimoto R; Nakaigawa N; Nagashima Y; Toyohara J; Ueno D; Namura K; Nakajima K; Yao M; Kubota K
Abdom Radiol (NY); 2016 Mar; 41(3):521-30. PubMed ID: 27039323
[TBL] [Abstract][Full Text] [Related]
2. 4'-[Methyl-11C]-thiothymidine PET/CT for proliferation imaging in non-small cell lung cancer.
Minamimoto R; Toyohara J; Seike A; Ito H; Endo H; Morooka M; Nakajima K; Mitsumoto T; Ito K; Okasaki M; Ishiwata K; Kubota K
J Nucl Med; 2012 Feb; 53(2):199-206. PubMed ID: 22190643
[TBL] [Abstract][Full Text] [Related]
3. 4'-[methyl-
Fukuda Y; Yamamoto Y; Mitamura K; Ishikawa R; Asano E; Toyohara J; Norikane T; Nishiyama Y
Ann Nucl Med; 2019 Nov; 33(11):822-827. PubMed ID: 31401773
[TBL] [Abstract][Full Text] [Related]
4. Correlation of 4'-[methyl-(11)C]-thiothymidine uptake with Ki-67 immunohistochemistry and tumor grade in patients with newly diagnosed gliomas in comparison with (11)C-methionine uptake.
Tanaka K; Yamamoto Y; Maeda Y; Yamamoto H; Kudomi N; Kawai N; Toyohara J; Nishiyama Y
Ann Nucl Med; 2016 Feb; 30(2):89-96. PubMed ID: 26511019
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of renal cell carcinoma histological subtype and fuhrman grade using
Nakajima R; Nozaki S; Kondo T; Nagashima Y; Abe K; Sakai S
Eur Radiol; 2017 Nov; 27(11):4866-4873. PubMed ID: 28523353
[TBL] [Abstract][Full Text] [Related]
6. Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report.
Namura K; Minamimoto R; Yao M; Makiyama K; Murakami T; Sano F; Hayashi N; Tateishi U; Ishigaki H; Kishida T; Miura T; Kobayashi K; Noguchi S; Inoue T; Kubota Y; Nakaigawa N
BMC Cancer; 2010 Dec; 10():667. PubMed ID: 21129184
[TBL] [Abstract][Full Text] [Related]
7. Clinical value of PET/CT with carbon-11 4DST in the evaluation of malignant and benign lung tumors.
Nishii R; Saga T; Sudo H; Togawa T; Kuyama J; Tani T; Maeda T; Kobayashi M; Iizasa T; Shingyoji M; Itami M; Kawamura K; Hashimoto H; Yamazaki K; Tamura K; Higashi T
Ann Nucl Med; 2021 Feb; 35(2):211-222. PubMed ID: 33387282
[TBL] [Abstract][Full Text] [Related]
8. Restaging clear cell renal carcinoma with 18F-FDG PET/CT.
Fuccio C; Ceci F; Castellucci P; Spinapolice EG; Palumbo R; D'Ambrosio D; Bernardo A; Brunocilla E; Schiavina R; Maffione AM; Chondrogiannis S; Grassetto G; Colletti PM; Rubello D; Fanti S; Trifirò G
Clin Nucl Med; 2014 Jun; 39(6):e320-4. PubMed ID: 24566409
[TBL] [Abstract][Full Text] [Related]
9. Preoperative evaluation of renal cell carcinoma by using 18F-FDG PET/CT.
Takahashi M; Kume H; Koyama K; Nakagawa T; Fujimura T; Morikawa T; Fukayama M; Homma Y; Ohtomo K; Momose T
Clin Nucl Med; 2015 Dec; 40(12):936-40. PubMed ID: 26164183
[TBL] [Abstract][Full Text] [Related]
10. Volumetric comparison of positron emission tomography/computed tomography using 4'-[methyl-¹¹C]-thiothymidine with 2-deoxy-2-¹⁸F-fluoro-D-glucose in patients with advanced head and neck squamous cell carcinoma.
Ito K; Yokoyama J; Miyata Y; Toyohara J; Okasaki M; Minamimoto R; Morooka M; Ishiwata K; Kubota K
Nucl Med Commun; 2015 Mar; 36(3):219-25. PubMed ID: 25369751
[TBL] [Abstract][Full Text] [Related]
11. Clinically significant association between the maximum standardized uptake value on 18F-FDG PET and expression of phosphorylated Akt and S6 kinase for prediction of the biological characteristics of renal cell cancer.
Mizuno T; Kamai T; Abe H; Sakamoto S; Kitajima K; Nishihara D; Yuki H; Kambara T; Betsunoh H; Yashi M; Fukabori Y; Kaji Y; Yoshida K
BMC Cancer; 2015; 15():1097. PubMed ID: 25784113
[TBL] [Abstract][Full Text] [Related]
12. Semi-quantitative F-18-FDG PET/computed tomography parameters for prediction of grade in patients with renal cell carcinoma and the incremental value of diuretics.
Singh H; Arora G; Nayak B; Sharma A; Singh G; Kumari K; Jana S; Patel C; Pandey AK; Seth A; Kumar R
Nucl Med Commun; 2020 May; 41(5):485-493. PubMed ID: 32168262
[TBL] [Abstract][Full Text] [Related]
13. The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy.
Nakaigawa N; Kondo K; Ueno D; Namura K; Makiyama K; Kobayashi K; Shioi K; Ikeda I; Kishida T; Kaneta T; Minamimoto R; Tateishi U; Inoue T; Yao M
BMC Cancer; 2017 Jan; 17(1):39. PubMed ID: 28068944
[TBL] [Abstract][Full Text] [Related]
14. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses.
Ozülker T; Ozülker F; Ozbek E; Ozpaçaci T
Nucl Med Commun; 2011 Apr; 32(4):265-72. PubMed ID: 21301376
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic performance and prognostic value of preoperative
Chen S; Zhao Y; Tang Q; Wu C; Wang A; Ma L; Zhang X; Chen J; Gao Y; Liao X; Feng N; Fan Y; Zhang J; Li X; Liu M
Cancer Imaging; 2022 Nov; 22(1):65. PubMed ID: 36435856
[TBL] [Abstract][Full Text] [Related]
16. One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival.
Ito H; Kondo K; Kawahara T; Kaneta T; Tateishi U; Ueno D; Namura K; Kobayashi K; Miyoshi Y; Yumura Y; Makiyama K; Hayashi N; Hasumi H; Osaka K; Yokomizo Y; Teranishi JI; Hattori Y; Inoue T; Uemura H; Yao M; Nakaigawa N
Cancer Chemother Pharmacol; 2017 May; 79(5):855-861. PubMed ID: 28331985
[TBL] [Abstract][Full Text] [Related]
17. Imaging of renal cell carcinoma in patients with acquired cystic disease of the kidney: comparison
Kitajima K; Yamamoto S; Kawanaka Y; Katsuura T; Fujita M; Nakanishi Y; Yamada Y; Hashimoto T; Suzuki T; Go S; Kanematsu A; Nojima M; Yamakado K
Jpn J Radiol; 2019 Feb; 37(2):165-177. PubMed ID: 30377936
[TBL] [Abstract][Full Text] [Related]
18. Early assessment with
Tabei T; Nakaigawa N; Kaneta T; Ikeda I; Kondo K; Makiyama K; Hasumi H; Hayashi N; Kawahara T; Izumi K; Osaka K; Muraoka K; Teranishi JI; Miyoshi Y; Yumura Y; Uemura H; Kobayashi K; Inoue T; Yao M
BMC Cancer; 2019 Apr; 19(1):298. PubMed ID: 30940117
[TBL] [Abstract][Full Text] [Related]
19. Dual-tracer PET/CT in renal angiomyolipoma and subtypes of renal cell carcinoma.
Ho CL; Chen S; Ho KM; Chan WK; Leung YL; Cheng KC; Wong KN; Cheung MK; Wong KK
Clin Nucl Med; 2012 Nov; 37(11):1075-82. PubMed ID: 22996247
[TBL] [Abstract][Full Text] [Related]
20. FDG PET/CT and CT Findings of Renal Cell Carcinoma With Sarcomatoid Differentiation.
Zhu H; Zhao S; Zuo C; Ren F
AJR Am J Roentgenol; 2020 Sep; 215(3):645-651. PubMed ID: 32755159
[No Abstract] [Full Text] [Related]
[Next] [New Search]